Genetic Testing for All Women? Not a Solution to the Breast Cancer Epidemic
By Karuna Jaggar,
Huffington Post
| 09. 24. 2014
The perseverance and scientific innovation of Dr. Mary Claire King, the geneticist whose efforts to identify the BRCA genes were initially scoffed at by her peers, cannot be underestimated or underappreciated. Her drive and desire to find better tools to address the breast cancer epidemic are shared by activists, researchers, geneticist, and patients alike. But her new recommendation, published in the Journal of the American Medical Association -- that all women in the United States over age 30 be screened for BRCA mutations linked to breast and ovarian cancer -- fails as a matter of public health to recognize the significant limitations, and harms, of mass genetic testing in the current health care environment.
In proposing that genetic testing for the BRCA1 and BRCA2 genes become routine for all women over age 30, Dr. King focuses only on what she sees as the potential benefit, of identifying women with genetic mutations that increase their risk of cancer, and minimizes the harms that result from exposing all 105,000,000 women age 30 and over in the U.S. to genetic testing without access...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...